<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102587/results/search/disease/results.xml">
  <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Diabetes" post="Metab SyndrDiabetes Metab SyndrDiabetes &amp;amp; Metabolic Syndrome1871-40211878-0334Diabetes India. Published"/>
  <result pre="∗Corresponding author. draksingh_2001@yahoo.com pmc-release: 2020-3-3ppub: 2020epub: 2020-3-3143241246received: 2020-3-21rev-recd: 2020-3-22accepted: 2020-3-22(C)" exact="Diabetes" post="India, 2020Since January 2020 Elsevier has created a COVID-19"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="experimental drugs. Since HCQ has been approved for treatment of" exact="diabetes" post="in India, it should be further researched in diabetes"/>
  <result pre="of diabetes in India, it should be further researched in" exact="diabetes" post="and COVID-19, a subgroup where significant mortality has been"/>
  <result pre="use of these drugs in COVID-19. Keywords COVID-19 Chloroquine Hydroxychloroquine" exact="Diabetes" post="1 Introduction Novel coronavirus (2019-nCoV), officially known as severe"/>
  <result pre="Diabetes 1 Introduction Novel coronavirus (2019-nCoV), officially known as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of"/>
  <result pre="1 Introduction Novel coronavirus (2019-nCoV), officially known as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the"/>
  <result pre="Introduction Novel coronavirus (2019-nCoV), officially known as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona" exact="Virus Disease" post="2019) COVID-19, emerged in Wuhan, Hubei province, China. On"/>
  <result pre="coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona Virus" exact="Disease" post="2019) COVID-19, emerged in Wuhan, Hubei province, China. On"/>
  <result pre="11th March 2020, The World Health Organization (WHO) declared this" exact="disease" post="as pandemic [1]. Chinese Centre for Disease Control and"/>
  <result pre="(WHO) declared this disease as pandemic [1]. Chinese Centre for" exact="Disease" post="Control and Prevention showed an increased mortality in people"/>
  <result pre="Control and Prevention showed an increased mortality in people with" exact="diabetes" post="(2.3% vs. 7.3%; overall vs. in patients with diabetes"/>
  <result pre="with diabetes (2.3% vs. 7.3%; overall vs. in patients with" exact="diabetes" post="respectively) from a report of 72,314 cases of COVID-19"/>
  <result pre="a report of 72,314 cases of COVID-19 [2]. People with" exact="diabetes" post="and COVID-19 may need special attention and clinical care"/>
  <result pre="may need special attention and clinical care [3]. In the" exact="absence of" post="any known efficient therapy and because of the situation"/>
  <result pre="drugs. Because HCQ has been approved in the treatment of" exact="type 2" post="diabetes in India since 2014 as a third- or"/>
  <result pre="HCQ has been approved in the treatment of type 2" exact="diabetes" post="in India since 2014 as a third- or fourth-line"/>
  <result pre="known, changes the pH of endosomes and believed to prevent" exact="viral" post="entry, transport and post-entry events Inhibits infection of cells"/>
  <result pre="believed to prevent viral entry, transport and post-entry events Inhibits" exact="infection" post="of cells by SARS-CoV-2 in vitro, approved for malaria"/>
  <result pre="Inhibits infection of cells by SARS-CoV-2 in vitro, approved for" exact="malaria" post="treatment and prophylaxis Hydroxychloroquine 4-aminoquinoline Not clearly known, changes"/>
  <result pre="known, changes the pH of endosomes and believed to prevents" exact="viral" post="entry, transport and post-entry events Inhibits infection of cells"/>
  <result pre="believed to prevents viral entry, transport and post-entry events Inhibits" exact="infection" post="of cells by SARS-CoV-2 in vitro, approved for malaria"/>
  <result pre="Inhibits infection of cells by SARS-CoV-2 in vitro, approved for" exact="malaria" post="prophylaxis and autoimmune disease (e.g. rheumatic diseases). Approved for"/>
  <result pre="cells by SARS-CoV-2 in vitro, approved for malaria prophylaxis and" exact="autoimmune" post="disease (e.g. rheumatic diseases). Approved for treatment of T2DM"/>
  <result pre="by SARS-CoV-2 in vitro, approved for malaria prophylaxis and autoimmune" exact="disease" post="(e.g. rheumatic diseases). Approved for treatment of T2DM in"/>
  <result pre="in vitro, approved for malaria prophylaxis and autoimmune disease (e.g." exact="rheumatic" post="diseases). Approved for treatment of T2DM in India Remdesivir"/>
  <result pre="treatment of T2DM in India Remdesivir Adenosine nucleotide analogues Inhibits" exact="viral" post="application Effective against SARS and MERS Ribavirin Nucleoside analogue"/>
  <result pre="application Effective against SARS and MERS Ribavirin Nucleoside analogue Inhibits" exact="viral" post="RNA synthesis and mRNA capping No evidence in SARS"/>
  <result pre="in SARS (potential harm) and MERS Ribavirin plus Interferon Inhibits" exact="viral" post="replication Mixed result against MERS Camostat Mesilate Protease inhibitors"/>
  <result pre="(potential harm) and MERS Ribavirin plus Interferon Inhibits viral replication" exact="Mixed" post="result against MERS Camostat Mesilate Protease inhibitors Blocks viral"/>
  <result pre="replication Mixed result against MERS Camostat Mesilate Protease inhibitors Blocks" exact="viral" post="maturation and entry to cells Effectively blocked SARS-CoV-2 in"/>
  <result pre="SARS-CoV-2 in lung cells in vitro Lopinavir/Ritonavir Protease inhibitors Blocks" exact="viral" post="cellular entry Effective against SARS-CoV-1 both in vitro and"/>
  <result pre="human studies, approved for HIV-1 treatment Darunavir/Cobicistat Protease inhibitors Blocks" exact="viral" post="cellular entry Established anti-HIV medication. No activity against coronaviruses"/>
  <result pre="entry Established anti-HIV medication. No activity against coronaviruses or other" exact="respiratory" post="viruses.No in vitro or clinical data. Favipiravir RNA polymerase"/>
  <result pre="in vitro or clinical data. Favipiravir RNA polymerase inhibitors Inhibits" exact="viral" post="RNA-dependent polymerase Broad-spectrum anti-viral against influenza, arenavirus, bunyavirus and"/>
  <result pre="arenavirus, bunyavirus and filovirus Umifenovir Fusion inhibitor Inhibits fusion between" exact="viral" post="and cellular membrane Antiviral against other Corona viruses Interferon-β1"/>
  <result pre="in animal studies. Interferon beta plus Lopinavir/Ritonavir Interferon beta inhibits" exact="viral" post="replication Ongoing study for SARS-Cov-2 and MIRACLE trial for"/>
  <result pre="Case report suggested benefit in MERS Oseltamivir Neuraminidase inhibitor Inhibits" exact="viral" post="replication No effect in SARS in vitro studies. No"/>
  <result pre="vitro studies. No evidence in SARS and MERS Baloxivir marboxil" exact="Viral" post="endonuclease inhibitor Inhibits influenza virus multiplication Approved for uncomplicated"/>
  <result pre="Tocilizumab reduced fever and oxygen requirement in COVID-19, approved for" exact="rheumatoid arthritis." post="SARS-Cov-2 specific protease drug candidate Protease inhibitors Blocks viral"/>
  <result pre="rheumatoid arthritis. SARS-Cov-2 specific protease drug candidate Protease inhibitors Blocks" exact="viral" post="infectivity No data available SARS-Cov-2 specific antibodies Antibody Binds"/>
  <result pre="inhibitors Blocks viral infectivity No data available SARS-Cov-2 specific antibodies" exact="Antibody" post="Binds to virus and block infection, binds to infected"/>
  <result pre="system Inhibits SARS-CoV-2 entry into cells in vitro SARS- severe" exact="acute" post="respiratory syndrome, MERS- Middle-East respiratory syndrome, HIV- Human Immunodeficiency"/>
  <result pre="Inhibits SARS-CoV-2 entry into cells in vitro SARS- severe acute" exact="respiratory" post="syndrome, MERS- Middle-East respiratory syndrome, HIV- Human Immunodeficiency syndrome,"/>
  <result pre="cells in vitro SARS- severe acute respiratory syndrome, MERS- Middle-East" exact="respiratory" post="syndrome, HIV- Human Immunodeficiency syndrome, T2DM – type 2"/>
  <result pre="severe acute respiratory syndrome, MERS- Middle-East respiratory syndrome, HIV- Human" exact="Immunodeficiency" post="syndrome, T2DM – type 2 diabetes, COVID-19- Corona virus"/>
  <result pre="MERS- Middle-East respiratory syndrome, HIV- Human Immunodeficiency syndrome, T2DM –" exact="type 2" post="diabetes, COVID-19- Corona virus disease 19. In this review"/>
  <result pre="Immunodeficiency syndrome, T2DM – type 2 diabetes, COVID-19- Corona virus" exact="disease" post="19. In this review article, we have systematically searched"/>
  <result pre="in the treatment of patients with COVID-19, with or without" exact="diabetes" post="and present a perspective on both these compounds. Additionally,"/>
  <result pre="chloroquine AND COVID-19, and hydroxychloroquine AND COVID-19 and retrieved a" exact="total" post="of 13 articles. The two articles that were written"/>
  <result pre="of SARS-CoV and thereby it has the potential to block" exact="viral infection" post="[7]. In addition, chloroquine also inhibits the quinone reductase-2,"/>
  <result pre="SARS-CoV and thereby it has the potential to block viral" exact="infection" post="[7]. In addition, chloroquine also inhibits the quinone reductase-2,"/>
  <result pre="by SARS-CoV-2) found chloroquine to be highly effective in reducing" exact="viral" post="replication that can be easily achievable with standard dosing"/>
  <result pre="vitro [12,13]. In addition, HCQ acts effectively on other intracellular" exact="bacterial infections" post="such as Coxiella burnetii (Q fever) and Tropheryma whipplei"/>
  <result pre="[12,13]. In addition, HCQ acts effectively on other intracellular bacterial" exact="infections" post="such as Coxiella burnetii (Q fever) and Tropheryma whipplei"/>
  <result pre="considered in severely sick patients is cytokine storm associated with" exact="disease" post="severity of SARS-CoV-2 [17].The significant decrease in the production"/>
  <result pre="and cytokines with HCQ has made this agent a successful" exact="disease" post="modifying anti-inflammatory agent in the treatment of various autoimmune"/>
  <result pre="successful disease modifying anti-inflammatory agent in the treatment of various" exact="autoimmune" post="diseases including rheumatoid arthritis, systemic lupus erythematosus and Sjogren’s"/>
  <result pre="anti-inflammatory agent in the treatment of various autoimmune diseases including" exact="rheumatoid arthritis," post="systemic lupus erythematosus and Sjogren’s syndrome. Long-term clinical safety"/>
  <result pre="in the treatment of various autoimmune diseases including rheumatoid arthritis," exact="systemic" post="lupus erythematosus and Sjogren’s syndrome. Long-term clinical safety profile"/>
  <result pre="the treatment of various autoimmune diseases including rheumatoid arthritis, systemic" exact="lupus erythematosus" post="and Sjogren’s syndrome. Long-term clinical safety profile of HCQ"/>
  <result pre="to the control group in reducing symptom duration, exacerbation of" exact="pneumonia" post="including radiological improvement and promoting virus-negative seroconversion without any"/>
  <result pre="of the Guidelines for the Prevention, Diagnosis, and Treatment of" exact="Pneumonia" post="Caused by COVID-19. In this study, chloroquine was given"/>
  <result pre="mg of chloroquine twice daily in mild to severe COVID-19" exact="pneumonia" post="(see Table 1). The second human study which is"/>
  <result pre="HCQ plus azithromycin was highly and significantly effective in clearing" exact="viral" post="nasopharyngeal carriage (measured by polymerase chain reaction [PCR]) in"/>
  <result pre="effect of HCQ was significantly higher (p &amp;lt; 0.05) in" exact="symptomatic" post="patients as compared to asymptomatic patients with COVID-19. The"/>
  <result pre="study; a small sample size, dropout of six patients and" exact="limited" post="follow-up, apart from the non-randomized and open-label nature of"/>
  <result pre="swab PCR to call it as a sample negative, was" exact="lower" post="(Ct value &amp;gt; 35 was deemed as negative for"/>
  <result pre="for the PCR test to turn positive. In other words," exact="lower" post="the number of Ct denotes more virus is present"/>
  <result pre="exaggerate the final results of this study. Nevertheless, based on" exact="limited" post="available evidences to date, and given the prevailing pandemic"/>
  <result pre="patients diagnosed as mild, moderate and severe cases of SARS-CoV-2" exact="pneumonia" post="in the absence of contraindication to the drug [21]."/>
  <result pre="mild, moderate and severe cases of SARS-CoV-2 pneumonia in the" exact="absence of" post="contraindication to the drug [21]. A Central Clinical Task"/>
  <result pre="in the absence of contraindication to the drug [21]. A" exact="Central" post="Clinical Task Force from Korea who have treated 27"/>
  <result pre="severe case of COVID-19 [22]. Similarly, The Dutch Center of" exact="Disease" post="control in a public document on its website, also"/>
  <result pre="suggested the use of chloroquine in those having severe COVID-19" exact="infection" post="admitted in the intensive care unit [23]. Table 2"/>
  <result pre="province, China21 Chloroquine phosphate 500 mg BID for 10 days." exact="Central" post="Clinical Task Force, Korea22 Moderate to severe COVID-19:Lopinavir 400mg/Ritonavir"/>
  <result pre="400 mg orally per day for 7–10 days. Centre for" exact="Disease" post="Control and Prevention, Atlanta, MICC Version 1 (March 12,"/>
  <result pre="150 mg BID for 5 days. The Dutch Center of" exact="Disease" post="Control24 600 mg of Chloroquine base followed by 300"/>
  <result pre="× 2/day per person on days 2–5. Italian Society of" exact="Infectious" post="and Tropical Diseases (Lombardy Section)25 Mild to moderate COVID-19:Lopinavir/ritonavir"/>
  <result pre="person on days 2–5. Italian Society of Infectious and Tropical" exact="Diseases" post="(Lombardy Section)25 Mild to moderate COVID-19:Lopinavir/ritonavir plus Chloroquine 500"/>
  <result pre="for 10 days. OD-once daily, BID-twice daily, TID-thrice daily, URTI-" exact="upper respiratory tract infection," post="PCR-polymerase chain reaction, i.v - intravenous. 4 Discussion The"/>
  <result pre="10 days. OD-once daily, BID-twice daily, TID-thrice daily, URTI- upper" exact="respiratory" post="tract infection, PCR-polymerase chain reaction, i.v - intravenous. 4"/>
  <result pre="chloroquine was seen in the prevention of influenza and dengue" exact="infection" post="in a randomized, double-blind, placebo-controlled, clinical trial [29,30]. Similarly,"/>
  <result pre="and influenza viruses [[31], [32], [33]]. Data of chloroquine against" exact="chikungunya" post="virus is even more intriguing. While chloroquine had satisfactory"/>
  <result pre="even more intriguing. While chloroquine had satisfactory antiviral activity against" exact="chikungunya" post="in vitro, animal studies showed increase in virus replication,"/>
  <result pre="studies showed increase in virus replication, aggravation of fever and" exact="incomplete" post="viral clearance [34]. Human trials of chloroquine showed no"/>
  <result pre="showed increase in virus replication, aggravation of fever and incomplete" exact="viral" post="clearance [34]. Human trials of chloroquine showed no improvement"/>
  <result pre="clearance [34]. Human trials of chloroquine showed no improvement in" exact="chikungunya" post="acute illness and rather an increase in chronic arthralgia"/>
  <result pre="[34]. Human trials of chloroquine showed no improvement in chikungunya" exact="acute" post="illness and rather an increase in chronic arthralgia was"/>
  <result pre="improvement in chikungunya acute illness and rather an increase in" exact="chronic" post="arthralgia was observed during post-illness period, compared to the"/>
  <result pre="to the controls [35]. The role of chloroquine against Human" exact="Immunodeficiency" post="Virus was inconclusive [36]. The only viral disease where"/>
  <result pre="chloroquine against Human Immunodeficiency Virus was inconclusive [36]. The only" exact="viral" post="disease where chloroquine was modestly effective so far before"/>
  <result pre="against Human Immunodeficiency Virus was inconclusive [36]. The only viral" exact="disease" post="where chloroquine was modestly effective so far before COVID-19"/>
  <result pre="chloroquine was modestly effective so far before COVID-19 era was" exact="chronic hepatitis" post="C suggesting an increased virological response to pegylated interferon"/>
  <result pre="was modestly effective so far before COVID-19 era was chronic" exact="hepatitis" post="C suggesting an increased virological response to pegylated interferon"/>
  <result pre="done against COVID-19, more promising than previous trial in other" exact="viral" post="diseases. Moreover, these drugs are of low cost, reasonably"/>
  <result pre="reasonably safe (see below), and widely available in countries where" exact="malaria" post="is endemic. 4.1 Cautions and contraindication with chloroquine and"/>
  <result pre="prolongation. Perform ECG daily if QTc is 450–500 msec. Additionally," exact="hypoglycemia" post="must be looked for in patients with diabetes especially"/>
  <result pre="msec. Additionally, hypoglycemia must be looked for in patients with" exact="diabetes" post="especially with concurrent use of chloroquine/HCQ and lopinavir/ritonavir. Chloroquine"/>
  <result pre="lopinavir/ritonavir and remdisivir for anticipated QTc prolongation. Finally, pharmacovigilance on" exact="visual" post="and mental disturbance is also closely required. Although there"/>
  <result pre="closely required. Although there are sporadic case reports of chloroquine-induced" exact="cardiomyopathy" post="and reversible heart failure in the literature, many studies"/>
  <result pre="there are sporadic case reports of chloroquine-induced cardiomyopathy and reversible" exact="heart" post="failure in the literature, many studies and large meta-analysis"/>
  <result pre="literature, many studies and large meta-analysis conducted in patients with" exact="rheumatoid arthritis" post="pointed to a reduced cardiovascular risk with both these"/>
  <result pre="many studies and large meta-analysis conducted in patients with rheumatoid" exact="arthritis" post="pointed to a reduced cardiovascular risk with both these"/>
  <result pre="conducted in patients with rheumatoid arthritis pointed to a reduced" exact="cardiovascular" post="risk with both these compounds [40]. Nevertheless, since both"/>
  <result pre="a baseline ECG should be done in patients with established" exact="cardiovascular disease." post="All clinicians using these drugs must know contraindication to"/>
  <result pre="using these drugs must know contraindication to both these compounds;" exact="hypersensitivity" post="to these agents, retinopathy, porphyria, epilepsy, pre-existing maculopathy, G6PD"/>
  <result pre="compounds; hypersensitivity to these agents, retinopathy, porphyria, epilepsy, pre-existing maculopathy," exact="G6PD deficiency," post="recent myocardial infarction and QTc &amp;gt;500 msec. Chloroquine is"/>
  <result pre="these agents, retinopathy, porphyria, epilepsy, pre-existing maculopathy, G6PD deficiency, recent" exact="myocardial infarction" post="and QTc &amp;gt;500 msec. Chloroquine is not contraindicated in"/>
  <result pre="pregnancy. 5 Conclusion Although evidence of chloroquine and HCQ is" exact="limited" post="(based on the experimental data and only two small"/>
  <result pre="the potentially favorable benefit-risk balance of chloroquine and HCQ in" exact="absence of" post="any other valid treatment option, we believe that such"/>
  <result pre="an effective strategy to counter COVID-19 (especially in patients with" exact="diabetes" post="and other co-morbidities in whom mortality is high) in"/>
  <result pre="can be used as an adjunct to control glycemia in" exact="adult" post="patients with type 2 diabetes (approved for treatment in"/>
  <result pre="as an adjunct to control glycemia in adult patients with" exact="type 2" post="diabetes (approved for treatment in India). However, role of"/>
  <result pre="adjunct to control glycemia in adult patients with type 2" exact="diabetes" post="(approved for treatment in India). However, role of such"/>
  <result pre="days.C. Monitor and watch for side effects∗ @ watch for" exact="hypoglycemia" post="in diabetes especially with concurrent use of lopinavir/ritonavir, $"/>
  <result pre="and watch for side effects∗ @ watch for hypoglycemia in" exact="diabetes" post="especially with concurrent use of lopinavir/ritonavir, $ should not"/>
  <result pre="with lopinavir/ritonavir and remdisivir due to increased QTc prolongation, ∗" exact="complete" post="blood count, renal, hepatic profile and ECG – watch"/>
  <result pre="hepatic profile and ECG – watch for QTc prolongation, URTI-" exact="upper respiratory tract infection," post="LRTI- lower respiratory tract infection, HCQ-hydroxychloroquine, BID – twice"/>
  <result pre="profile and ECG – watch for QTc prolongation, URTI- upper" exact="respiratory" post="tract infection, LRTI- lower respiratory tract infection, HCQ-hydroxychloroquine, BID"/>
  <result pre="watch for QTc prolongation, URTI- upper respiratory tract infection, LRTI-" exact="lower" post="respiratory tract infection, HCQ-hydroxychloroquine, BID – twice daily. Table"/>
  <result pre="for QTc prolongation, URTI- upper respiratory tract infection, LRTI- lower" exact="respiratory" post="tract infection, HCQ-hydroxychloroquine, BID – twice daily. Table 4"/>
  <result pre="plus Chloroquine PBO 80 Thailand NCT04303299 Chloroquine Prevention of Coronavirus" exact="Disease" post="(COVID-19) in the Healthcare Setting (COPCOV) Prophylaxis Chloroquine PBO"/>
  <result pre="Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19" exact="Epidemic" post="(HCQ4COV19) Treatment and prophylaxis in two separate groups Darunavir/Cobicistat"/>
  <result pre="Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus" exact="Disease" post="(COVID-19) Treatment Lopinavir/ritonavir HCQ 150 Korea NCT04307693 Efficacy and"/>
  <result pre="Korea NCT04307693 Efficacy and Safety of Hydroxychloroquine for Treatment of" exact="Pneumonia" post="Caused by 2019-nCoV (HC-nCoV) Treatment HCQ PBO 30 China"/>
  <result pre="tested in further studies. 4.Use of HCQ in patients with" exact="diabetes" post="in India where it is already approved for treatment:"/>
  <result pre="approved for treatment: It would be interesting to research COVID-19" exact="infection" post="in patients with diabetes who are already on HCQ"/>
  <result pre="would be interesting to research COVID-19 infection in patients with" exact="diabetes" post="who are already on HCQ for treatment of diabetes."/>
  <result pre="treatment of diabetes. Further, the effect of HCQ on glycemia," exact="cardiovascular" post="function and viral load, in patients with diabetes needs"/>
  <result pre="Further, the effect of HCQ on glycemia, cardiovascular function and" exact="viral" post="load, in patients with diabetes needs to be researched."/>
  <result pre="on glycemia, cardiovascular function and viral load, in patients with" exact="diabetes" post="needs to be researched. Declaration of competing interest We"/>
  <result pre="11 March 2020https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020 2WuZ.McGooganJ.M.Characteristics of and important lessons from the" exact="coronavirus disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="March 2020https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020 2WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese center for" exact="disease" post="control and preventionJ Am Med Assoc2020 Feb 2410.1001/jama.2020.2648 3GuptaR.GhoshA.SinghA.K.MisraA.Clinical"/>
  <result pre="Am Med Assoc2020 Feb 2410.1001/jama.2020.2648 3GuptaR.GhoshA.SinghA.K.MisraA.Clinical considerations for patients with" exact="diabetes" post="in times of COVID-19 epidemicDiabetes, Metab Syndrome Clin Res"/>
  <result pre="for patients with diabetes in times of COVID-19 epidemicDiabetes, Metab" exact="Syndrome" post="Clin Res Rev1432020 Mar 10211212 4LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Asymptomatic carrier state, acute"/>
  <result pre="Metab Syndrome Clin Res Rev1432020 Mar 10211212 4LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Asymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
  <result pre="Syndrome Clin Res Rev1432020 Mar 10211212 4LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Asymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
  <result pre="Rev1432020 Mar 10211212 4LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Asymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
  <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and mythsJ Microbiol"/>
  <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): facts and mythsJ Microbiol Immunol"/>
  <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): facts and mythsJ Microbiol Immunol Infect202020"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChembiochem42020 Feb10.1038/s41422-020-0282-0 6LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Drug treatment options"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChembiochem42020 Feb10.1038/s41422-020-0282-0 6LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Drug treatment options for"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChembiochem42020 Feb10.1038/s41422-020-0282-0 6LaiC.C.LiuY.H.WangC.Y.WangY.H.HsuehS.C.YenM.Y.Drug treatment options for the"/>
  <result pre="endosome/lysosome and block the entry of Ebola virus, middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
  <result pre="and block the entry of Ebola virus, middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)J"/>
  <result pre="Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)J Biol Chem29120169218e3226953343 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine"/>
  <result pre="virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)J Biol Chem29120169218e3226953343 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine as"/>
  <result pre="middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)J Biol Chem29120169218e3226953343 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine as available"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov620201610.1038/s41421-020-0156-032194981 13YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In vitro antiviral activity and projection"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii:"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237,"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237, [Epub"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends202010.5582/bst.2020.01047 19GautretP.LagieraJ.C.ParolaaP.HoangaV.T.MeddebaL.MailheaM.Hydroxychloroquine and azithromycin as a"/>
  <result pre="of Guangdong Province for chloroquine in the treatment of novel" exact="coronavirus pneumonia." post="Expert consensus on chloroquine phosphate for the treatment of"/>
  <result pre="March 2020 26Mount Sinai health system treatment guidelines for SARS-CoV-2" exact="infection" post="(COVID-19)https://www.mountsinai.org/health-library/diseases-conditions/2019-novel-coronavirus-2019-ncovLast accessed on 20th March 2020 27https://www.esicm.org/ssc-covid19-guidelines/Last accessed on"/>
  <result pre="in vivoInfluenza Other Respir Viruses1200718919219453426 33PallisterJ.MiddletonD.CrameriG.YamadaM.KleinR.Chloroquine administration does not prevent" exact="Nipah virus infection" post="and disease in ferretsJ Virol832009119791198219759137 34SethP.ManH.SinghA.K.BanaudhaK.K.MadhavanS.SidhuG.S.Acceleration of viral replication"/>
  <result pre="vivoInfluenza Other Respir Viruses1200718919219453426 33PallisterJ.MiddletonD.CrameriG.YamadaM.KleinR.Chloroquine administration does not prevent Nipah" exact="virus infection" post="and disease in ferretsJ Virol832009119791198219759137 34SethP.ManH.SinghA.K.BanaudhaK.K.MadhavanS.SidhuG.S.Acceleration of viral replication"/>
  <result pre="Other Respir Viruses1200718919219453426 33PallisterJ.MiddletonD.CrameriG.YamadaM.KleinR.Chloroquine administration does not prevent Nipah virus" exact="infection" post="and disease in ferretsJ Virol832009119791198219759137 34SethP.ManH.SinghA.K.BanaudhaK.K.MadhavanS.SidhuG.S.Acceleration of viral replication"/>
  <result pre="Viruses1200718919219453426 33PallisterJ.MiddletonD.CrameriG.YamadaM.KleinR.Chloroquine administration does not prevent Nipah virus infection and" exact="disease" post="in ferretsJ Virol832009119791198219759137 34SethP.ManH.SinghA.K.BanaudhaK.K.MadhavanS.SidhuG.S.Acceleration of viral replication and up-regulation"/>
  <result pre="Nipah virus infection and disease in ferretsJ Virol832009119791198219759137 34SethP.ManH.SinghA.K.BanaudhaK.K.MadhavanS.SidhuG.S.Acceleration of" exact="viral" post="replication and up-regulation of cytokine levels by antimalarials: implications"/>
  <result pre="Trop Med Hyg61199918018610463664 35RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of chloroquine treatment in enhancing" exact="chikungunya" post="virus infectionViruses1052018 May 1710.3390/v10050268pii: E268 36ChauhanA.TikooA.The enigma of the"/>
  <result pre="early virological response to pegylated interferon plus ribavirin in genotype-4" exact="chronic hepatitis" post="C patientsJ Med Virol881220162170217827183377 38Chloroquine US prescribing information(Last accessed"/>
  <result pre="virological response to pegylated interferon plus ribavirin in genotype-4 chronic" exact="hepatitis" post="C patientsJ Med Virol881220162170217827183377 38Chloroquine US prescribing information(Last accessed"/>
  <result pre="March 21, 2020)https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf 40LiuD.LiX.ZhangY.KwongJ.S.W.LiL.ZhangY.Chloroquine and hydroxychloroquine are associated with reduced" exact="cardiovascular" post="risk: a systematic review and meta-analysisDrug Des Dev Ther12201816851695"/>
  <result pre="for empiric use of hydroxychloroquine for prophylaxis of SARS CoV-2" exact="infection" post=""/>
 </snippets>
</snippetsTree>
